Xtalks — The Life Science Community™, Online webinar
2026-12-14
Psychedelic therapies are rapidly emerging as one of the most promising areas of innovation in central nervous system (CNS) research, offering potential new treatment approaches for individuals living with conditions such as depression, post-traumatic stress disorder (PTSD), anxiety, substance use disorders and other mental health challenges. As scientific understanding of these compounds continues to evolve, researchers are investigating their therapeutic potential to treat mental health disorders. This webinar explores the scientific advances, clinical development considerations and regulatory challenges shaping the future of psychedelic therapies for CNS diseases. Ongoing research is examining the neurobiological mechanisms underlying psychedelic therapies and their potential to produce sustained therapeutic effects. However, translating these findings into clinical applications requires careful consideration of study design, treatment outcomes, safety and regulatory expectations. The featured speakers will examine the current clinical development landscape, emerging biomarkers and endpoints, regulatory considerations and the role psychedelics may play in the future of personalized mental health care. Attendees will gain insights into ongoing clinical research, challenges in evaluating therapeutic efficacy and opportunities to develop more individualized treatment approaches. Register for this webinar to learn about emerging psychedelic therapies for CNS diseases, the challenges of clinical development and the regulatory considerations shaping future treatment strategies.
|
|
|
Invited Speakers:
|
|
Bob Dagher, MD, Chief Medical Officer, Clinilabs Michael Gold, MD, Chief Research and Development Officer, Compass Pathways Joseph Tucker, PhD, CEO & Director, Enveric Biosciences Alan Metz, MD, Founder, Alan Metz Consulting LLC
|
|